GSK believes in vaccine battle against Pfizer – now shipping first Arexvy dose
British pharmaceutical company GSK is optimistic about the market outlook for its newly approved RSV vaccine, Arexvy, for older adults. Now GSK is also sending the first dose to US distribution centers, reports industry media Endpoint News.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Bavarian Nordic CEO says R&D efforts won't be discontinued
For subscribers
Moderna seeks approval in Europe and the US for RSV vaccine
For subscribers